Last reviewed · How we verify
Ondansetron Orally Disintegrating Tablets 8 mg
Ondansetron Orally Disintegrating Tablets 8 mg is a Small molecule drug developed by Mylan Pharmaceuticals Inc. It is currently in Phase 1 development.
At a glance
| Generic name | Ondansetron Orally Disintegrating Tablets 8 mg |
|---|---|
| Sponsor | Mylan Pharmaceuticals Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Alanine aminotransferase increased
- Abdominal Pain
- Eosinophil count increased
- Vomiting
- White blood cell count increased
- Upper respiratory tract infection
- Aspartate aminotransferase increased
- Total bilirubin increased
- Platelet count decreased
- Lymphocyte count increased
Key clinical trials
- A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity (PHASE1)
- Noninvasive Markers of Functional Nausea in Children (EARLY_PHASE1)
- Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions (PHASE1)
- Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions (PHASE1)
- Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg (PHASE1)
- Food Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg (PHASE1)
- Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets (PHASE1, PHASE2)
- Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ondansetron Orally Disintegrating Tablets 8 mg CI brief — competitive landscape report
- Ondansetron Orally Disintegrating Tablets 8 mg updates RSS · CI watch RSS
- Mylan Pharmaceuticals Inc portfolio CI
Frequently asked questions about Ondansetron Orally Disintegrating Tablets 8 mg
What is Ondansetron Orally Disintegrating Tablets 8 mg?
Ondansetron Orally Disintegrating Tablets 8 mg is a Small molecule drug developed by Mylan Pharmaceuticals Inc.
Who makes Ondansetron Orally Disintegrating Tablets 8 mg?
Ondansetron Orally Disintegrating Tablets 8 mg is developed by Mylan Pharmaceuticals Inc (see full Mylan Pharmaceuticals Inc pipeline at /company/mylan-pharmaceuticals-inc).
What development phase is Ondansetron Orally Disintegrating Tablets 8 mg in?
Ondansetron Orally Disintegrating Tablets 8 mg is in Phase 1.
What are the side effects of Ondansetron Orally Disintegrating Tablets 8 mg?
Common side effects of Ondansetron Orally Disintegrating Tablets 8 mg include Alanine aminotransferase increased, Abdominal Pain, Eosinophil count increased, Vomiting, White blood cell count increased, Upper respiratory tract infection.